ANAdrian Nowak

Adrian Nowak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrian Nowak has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incretin-Based Therapies and the Associated Impact on Bone Health

    by Krzysztof Łupina, Miłosz Bronowski, Natalia Dardzińska, Paulina Jaskulska, Adrian Nowak, Anna Romac, Piotr Różański, Jakub Janczura

    Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.

  • The Liver-Bone Axis in Steatotic Liver Disease

    by Krzysztof Łupina, Adrian Nowak, Anna Romac, Paulina Jaskulska, Weronika StęPień, Aleksandra Kalisz, Kamil Jończyk, Jakub Janczura

  • Open Access

    Implementation of noninvasive liver disease screening tools in primary care

    by Klaudia Nowak, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Natalia Dardzińska, Jakub Janczura

    The global increase in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects more than one-third of the general population and up to 70% of individuals with type 2 diabetes or obesity, is a critical public health challenge. Given that liver steatosis is often asymptomatic until the advanced stages of disease, early detection is essential to prevent its progression to fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma. However, liver biopsy, the gold-standard diagnostic method, is invasive, costly, and unsuitable for large-scale screening. As a result, noninvasive tests have emerged as practical alternatives, particularly in primary care settings, where early identification is most feasible. The present study explored current perspectives of noninvasive liver disease screening tools and their implementation in primary care. Serum-based indices, along with imaging techniques, have demonstrated promise in identifying patients with advanced fibrosis. Novel biomarkers, including the enhanced liver fibrosis test and Pro-C3, as well as emerging artificial intelligence-assisted diagnostic platforms, yield improved accuracy and risk stratification potential. Despite accumulating evidence supporting the clinical utility and cost-effectiveness of noninvasive tests, several barriers hinder their routine use in primary care settings, which include limited funding, lack of standardized guidelines, insufficient clinician training, and disparities in access to diagnostic tools. The implementation of structured stepwise screening models has demonstrated improved diagnostic efficiency and reduced unnecessary referrals. Future research should emphasize the integration of artificial intelligence, portable diagnostic devices, and personalized risk models to enhance early detection. Ensuring widespread adoption requires coordinated efforts in policy development, provider education, and health-system investment. Noninvasive screening tools offer a feasible and cost-effective pathway for the early detection of MASLD in primary care; however, their successful implementation depends on addressing logistical, educational, and systemic barriers.


  • Open Access

    Herb-Induced Liver Injury

    by Krzysztof Łupina, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Łucja Ilkiewicz, Aleksandra Kalisz, Jakub Janczura

    Herb-induced liver injury (HILI) is an increasingly recognized cause of liver damage, associated with the widespread global use of herbal products. Despite its rising incidence, HILI remains underrecognized and underreported due to the absence of specific biomarkers, limited regulatory oversight, and the complexity of multi-ingredient formulations. Diagnostic efforts rely heavily on the Roussel Uclaf Causality Assessment Method (RUCAM), with clinical presentations often nonspecific and dominated by hepatocellular patterns of injury. Epidemiological data demonstrate regional variation, with notably higher case numbers in Asia and the Americas. Mechanistically, HILI may result from either intrinsic (predictable, dose-dependent) or idiosyncratic (unpredictable, immune-mediated) reactions. Genetic predispositions, including certain HLA alleles, have been identified as risk factors. Hepatotoxicity is often linked to specific phytochemicals such as pyrrolizidine alkaloids, catechins, anthraquinones, and diterpenoids, which may contribute to oxidative stress, mitochondrial damage, or immune activation. Additionally, product inconsistencies and contamination complicate risk assessment and safety evaluation. Current management focuses on immediate discontinuation of the suspected product and supportive care, though severe cases may require liver transplantation. Future directions include the development of specific diagnostic tools, implementation of globally harmonized regulatory standards, improved pharmacovigilance systems, and enhanced public and professional education. Addressing these priorities is crucial for reducing HILI-related morbidity while supporting the safe use of herbal therapies.


  • Open Access

    Pharmacological advances in HIV treatment: from ART to long-acting injectable therapies

    by Krzysztof Łupina, Klaudia Nowak, Dominika Lorek, Adrian Nowak, Anna Romac, Ewelina Głowacka, Jakub Janczura

    Human immunodeficiency virus (HIV) remains a global public health challenge, affecting millions worldwide despite significant advancements in antiretroviral therapy (ART). While ART has transformed HIV into a manageable chronic condition, long-term adherence, drug resistance, and access disparities continue to hinder treatment success. Recent research has focused on developing alternative therapeutic strategies, particularly long-acting injectable (LAI) therapies and immunotherapeutic approaches to improve adherence and potentially achieve viral remission. This review explores the evolution of pharmacological advancements in HIV treatment, highlighting the transition from daily oral ART to long-acting formulations such as cabotegravir, rilpivirine, and lenacapavir. LAI therapies reduce the burden of daily adherence, enhance treatment efficacy, and decrease stigma, particularly in vulnerable populations. Additionally, novel immunotherapeutic strategies such as broadly neutralizing antibodies, immune checkpoint inhibitors, and chimeric antigen receptor T cell therapy are being investigated for their potential to induce long-term viral suppression or cure. Despite these promising developments, several challenges remain, including resistance-associated mutations, accessibility issues, and long-term safety concerns. This review summarizes recent clinical trials, discusses the benefits and limitations of emerging HIV therapies, and outlines future research directions. The continued advancement of LAI therapies and immunotherapeutics holds great potential to improve treatment outcomes, expand global access to care, and move closer to a functional cure for HIV.